DOCSLIB.ORG

Appendix: Drug Names

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix: Drug Names APPENDIX: DRUG NAMES Chemical name Proprietary (trade) name acetylcholine Miochol adrenaline Eppy a1phaxolone Althesin a1prenolol Betacard amantadine Symmetrel amethocaine Gingicaine aminophyUine Cardophylin, Phyllocontin amitriptyline Tryptizol, Domical (+)-amphetamine Dexedrine, Benzedrine amylobarbitone Amytal apomorphine atropine Atropinol, Metropine bac10fen Lioresal bemegride Megimide benserazide (+ L-DOPA) Madopar benzhexol Artane benztropine Cogentin betazole Histalog bethanechol Mechothane, Myotonine chloride bethanidine Esbatal bretylium Bretylate, Darenthin bromocriptine Parlodel bupivacaine Marcain buprenorpbin Temgesic carbachol lsopto Carbachol carbamazepine Tegretol carbidopa (+ L-DOPA) Sinemet chloral hydrate Noctec chlordiazepoxide Librium, Calmoden chlorpheniramine Haynon, Piriton chlorphentermine Lucofen chlorpromazine Largactil, Chloractil chlorprothixene Taractan cimetidine Tagamet cinchocaine Nupercaine clomipramine Anafranil c10nazepam Rivotril c10nidine Catapres, Dixarit c10zapine Leponex cocaine codeine Tercoda, Terpalin, Terpain cyproheptadine Periactin debrisoquine Declinax decamethonium Eulissin, Syncurine deprenyl (selegiline) Eldepryl desipramine Pertofran diazepam Valium 192 Appendix 193 diethylpropion Tenuate diphenhydramine Benadryl, Benylin disodium cromoglycate Intal disulfiram Antabuse L-DOPA Larodopa, Berkdopa, Brocadopa dopamine Intropin edrophonium Tensilon ephedrine Endrine ethosuximide Emeside, Zarontin felypressin Octapressin fenfluramine Ponderax flupenthixol Depixol, Fluanxol fluphenazine Moditen fluphenazine decanoate Modecate flurazepam DaImane gallamine Flaxedil guanethidine Isme1in haloperidol Serenace, Haldol halothane Fluothane heroin Diamorphine HCI hexamethonium Vegolysen, Hexathide hexobarbitone Cyclonal sodium, Evidorm histamine hyoscine Pamine, Buscopan imipramine Tofranil, Norpramine ipratropium Atrovent iproniazid Marsilid isocarboxazid Marplan isoprenaline Saventrine, A1eudrin, Suscardia labetolol Trandate leptazol Cardiazol levallorphan Lorfan levorphanol Dromoran lignocaine Xylocaine, Lidothesin lithium carbonate Camcolit, Priadel lorazepam Ativan mazindol Teronac mecamylamine Inversine mepyramine Anthisan metaraminol Aramine methacholine Amechol, Mecholyl methadone Amidone, Physeptone methixene Tremonil methohexitone Brietal methoxamine Vasoxine, Vasylox methylamphetamine Methadrine a.-methylDOPA Aldomet, Dopamet, Medomet methylphenidate Ritalin methysergide Deseril metoclopramide Maxolon, Primperan mianserin Bolvidon, Norval morphine Duromorph nalorphine Lethidrone naloxone Narcan 194 Appendix naphazoline Privine neostigmine Prostigmin nialamide Niamid nikethamide Coramine nitrazepam Mogadon, Remnos nomifensine Merital noradrenaline Levophed nortriptyline Allegran, A ventyl orphenadrine Disipal oxazepam Serenid-D oxprenolol Trasicor oxymetazoline Iliadin-mini pancuronium Pavulon pargyline Eutonyl pempidine Perolysen penfluridol Semap pentagastrin Peptavlon pentazocine Fortral pentobarbitone Nembutal pethidine phenazocine Narphen phenelzine Nardil phenmetrazine Filon, Freludin phenobarbitone Parabal phenoperidine Operidine phenoxybenzarnine Dibenyline phentermine Duromine, lonamin phentolamine Rogitine phenylephrine Neophryn, Fenox phenylpropanolamine Eskornade, Rinurel phenytoin Epanutin physostigmine Antilirium pilocarpine Ocusert, Sno-Pilo pimozide Orap piribedil Trivastal practolol Eraldin pralidoxime Protopam prazosin Hypovase primidone Mysoline proCRine Novutox promethazine Phenergan propranolol Inderal protriptyline Concordin pyridostigmine Mestinon quinalbarbitone Seconal sodium ranitidine Zantac reserpine Serpasil salbutamol Ventolin sotalol Beta-Cardone spiperone (spiroperidol) Spiropitan sulpiride Dogmatil suxamethonium Anectine, Brevidil temazepam Normison, Euhypnos terbutaline Bricanyl Appendix 195 tetrabenazine Nitoman theobromine theophylline Entair, Aminomed, Nue\in thiopentone sodium Pentothal, Intraval thioridazine Melleril thiothixene Navane tranylcypromine Parnate trifluperidol Triperidol tropicamide Mydriacyl troxidone Tridione L-tryptophan Optimax, Pacitron (+ )-tubocurarine Tubarine tyramine Mydrial valproate sodium Epilim viloxazine Vivalan atenolol Tenormin butorphanol Stadol homatropine INDEX acetaldehyde 68, 185 akathesia 99-100 acetylcholine 22-41, 159; distribution akinesia 89-90 22,25-8; inactivation 31-2, L-oc-aJanine 127, 139 37-41; receptors 11, 24-31, 33-7, j3-a1anine 127, 133 agonists 28-9, 33, blockers 29-30, alcohol see ethanol 33-5, muscarinic 25-8, 33; aldosterone 59 nicotinic agonists 27-8, agonists aIlergic response 67,117, 118, 187 29, 35, blockers 30-1, 35-7; a1lyglycine 129 release 23-4, 33, 152, 154; a1phadolone acetate 190 storage 23, 32; summary of drugs a1phaxalone 190 affecting 38-9; synthesis 22-3 a1prenolol 79 acetylcholinesterase 13, 28, 31, Alzheimer's disease 32-3 37-40; inhibitors of 31-2, 35, 37, AmtJnita muscaria 28, 133 40; plasma cholinesterase 31-2, amantadine 83, 92 37-4 amenorrhoea 95,99 y-acetylenic GABA 134 amethocaine 189 acetylsalicylic acid see aspirin amino acid neurotransmitters acromegaly 95-6 127-44 ACTH 150, 152, 162-4 lC-aminobutyrlc acid see GABA action potential 4 cis-1,3-aminocyclohexane carboxylic acupuncture 151-2 acid 133 adenosine 51, 171-3; receptors amino-oxyacetic acid 134 172-3 D-oc-aInino-adipate 141 adenosine triphosphate (ATP) 11,23, 2-amino-5-phosphono-pentanoic acid 45-6,82,171 141 S-adenosyl-L-methionine 64-5, 89, aminophylline 57, 62, 72, 87,172, 122, 170 177 adenylate cyclase 11,51,84,86-7, 3-aminopropane sulphonic acid 138 131, 169, 172; inhibition of 51, amitriptyline 35, 63, 75, 107, 110, 86 114 adrenaline 42-3, 48-9, 54-6,63, (+)-amphetamine: and dopamine 83, 70-1, 168-9, 189 86,88,92,94,100,179;and adrenal medulla 22,25,27,42-3,57, 5-HT 107; and noradrenaline 47, 63,65,152,168 56,63,68,14,77 adrenergic neurone blockers 48, amylobarbitone 182-3, 187 68-70,76 anaesthesia: general 72, 182, 189-90; adrenoceptors 48-62; a1pha-adreno­ infiltration 189; local 4, 48, 58, ceptors 48-50, 168; beta-adreno­ 63, 70, 188-9; premedication 29, ceptors 49-53, 62, 71, 168; 34, 125, 182, 184 agonists 49, 55-6, 71-2; blockers analeptics 176 49, 58-9,72, 73-4; indirectly analgesics 75, 98, 150-7, 160, 175, acting agonists 47,53,56-7,68, 189-90 77 anaphylaxis 118-19 ADTN 86 angina 58, 73 affective disorders see depression angiotensin 43, 59, 160-1 mania anorectics 94, 101, 107, 113, 114 affmity 10 anorexia nervosa 94, 98, 114 agonists 8,9 antagonist 9 196 Index 197 anti-arrhythmic drugs 68, 73 axonal membrane 4 anticholinergics see acetylcholine axonal transport 3-4, 46, 147 receptor blockers anticholinesterases see acetylcholin­ baclofen 130, 135 esterase inhibitors barbitone 182-3 anticonvulsants 135, 143, 177-81, barbiturates 76, 80,131,137,157, 182, 183-5 162, 176-7, 179-83, 187, 190 antidepressants: MAO inhibitors 47, baroreceptor reflex 36, 54, 120 64-7,69-70,74-5,77-80,89, basal ganglia 85,108,131-2,134-5, 101, 111, 116, 170-1, 179, 187; 151, 158, 160-1 tricyclic compounds 35, 63, 66, basophils 117, 118 69,74-6, 107, 110, 114-16, 133, bemegride 176 179, 187; see also lithium benserazide 82, 90-1 antidiuretic hormone 165-6 benzhexol30, 34,88,92,100 anti-emetics see emesis benzodiazepines 76, 131, 133, 135, antigen-antibody reaction 37, 117, 179-81, 183-7 118-19, 122-3, 176 benztropine 30, 34, 88, 92, 100 antihistamines see histamine: benzylpenicillin 133 blockers, receptors betazole 121, 124 antihypertensives 30,35-6,58-9, bethanechol 29, 33 67-73,92 bethanidine 48, 68-70 antipsychotics see neuroleptics bicuculline 129-30, 133 antitussives 151, 155, 157 black widow spider venom 24, 31, 33 anxiolytics 182-5 bladder 27, 29,33,50 apomorphine 86, 95 blood vessels 26, 29, 50, 64, 68, 120, appetite stimulants 110, 113-14 133, 159; see also vasoconstriction, arachidonic acid 173 vasodilation area postrema 95, 151 bombesin 149 arecoline 29 botulinum toxin 24, 33, 49, 55-6 L-aromatic amino acid decarboxylase bradykinin 118, 123, 160 42,81-2,105,117; inhibitors of brain 28, 32, 52-3, 84-6, 89-101, 44,82,90-1, 105 108,120,131-8, 140, 151-64 arousal 28, 57, 120 bretylium 48, 69-70 aspartate aminotransferase 139 2-bromo- o£-ergocryptine aspartic acid 139-42; aminotrans- (bromocryptine) 86, 92, 95-6 aminase 139; distribution 140; 2-bromo-LSD 110 inactivation 141-2; receptors bronchoconstriction 34, 71, 74, 108, 140-1; release 140; storage 139; 119, 123-4, 155, 172 synthesis 139 bronchodilation 50-1, 56, 71-2, aspirin 174-5 159, 172-3, 175, 177 asthma 30, 56, 71-2,108,119,123, bupivocaine 189 173, 175-6 buprenorphin 155 atenolol73 burimamide 121 atherosclerosis 175 butorphanol 154 ATP see adenosine triphosphate butyrophenones 86-7,97-9,108,135 Atropa belladonna 35 butyrylcholinesterase see plasma atropine 29, 34-5, 40, 92, 125, 171, cholinesterase 174 autocoids 118 caffeine 51, 62, 72, 87, 172, 177 autonomic nervous system (ANS): calcium 8, 12, 24,47,83, 147 15; parasympathetic 15, 22 cannabis 190-1 passim 24-7; sympathetic 15, 22 capillary permeability 120 passim 25-7, 42, 48-9, 52, 84 carbachol 29, 33 autoreceptors 87-8, 148 carbamazepine 179-80 198 Index carbidopa 44,82, 9071, 106 compound 48-80, 118-19 l3-carboline 184 constipation 35-6, 75, 92, 99, 152, carcinoid tumour 108, 110, 114 156 cardiac arrhythmias 26, 50, 68-71, convulsants 135, 140, passim 73-8, 143, 188-90 passim convulsions 76, 99, 135, 138, 140, carotid body 84 155,176-81,183,188; see also catecholamine 42, 181; see epilepsy adrenaline, dopamine, cortex, cerebral 53, 85, 108, 140, noradrenaline lSI, 158-65 catechol-O-methyl
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0203752 A1 Blough Et Al
    US 201302O3752A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0203752 A1 Blough et al. (43) Pub. Date: Aug. 8, 2013 (54) PHENYLMORPHOLINES AND ANALOGUES Publication Classification THEREOF (51) Int. Cl. (76) Inventors: Bruce E. Blough, Raleigh, NC (US); C07D 265/30 (2006.01) Richard Rothman, Ellicott City, MD (52) U.S. Cl. (US); Antonio Landavazo, Raleigh, NC CPC .................................... C07D 265/30 (2013.01) (US); Kevin M. Page, Willow Spring, USPC ......... 514/231.2: 544/106; 544/174: 544/163 NC (US); Ann Marie Decker, Durham, NC (US) (57) ABSTRACT (21) Appl. No.: 13/698,892 Provided herein are compounds and prodrugs and methods of (22) PCT Filed: May 20, 2011 preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or (86). PCT No.: PCT/US2011/037361 more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceu S371 (c)(1), tical compositipos1u1ons compris1ng one or more OIf uneseth com (2), (4) Date: Mar. 4, 2013 pounds or prodrugs, which may further comprise one or more Related U.S. Application Data additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to (60) Provisional application No. 61/347,259, filed on May modification of monoamine neutrotransmitter levels, such as 21, 2010. pre-obesity, obesity, addiction, and depression. US 2013/0203752 A1 Aug. 8, 2013 PHENYLMORPHOLINES AND ANALOGUES 0006 Another anorectic, which was prescribed for the THEREOF short-term treatment of obesity, is phenmetrazine Phenmetra Zine is reportedly a potent Substrate for norephinephrine and FEDERALLY SPONSORED RESEARCHOR dopamine transporters and displays stimulant properties DEVELOPMENT similar to those of amphetamines.
    [Show full text]
  • ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0
    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0 USER MANUAL December 2020 Department of Veterans Affairs Office of Information and Technology (OIT) Product Development Revision History Date Description (Patch # if applicable) Project Manager Technical Writer 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx Claims Report ePharmacy ePharmacy Screen Display Development TeamDevelopment Team Updated Title Page date and footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx. 05/2017 Updated for BPS*1*21 REDACTED REDACTED 08/2016 Updated for BPS*1*20 REDACTED
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • The Use of Boron-Doped Diamond Electrode for the Determination of Selected Biocides in Water Samples
    water Article The Use of Boron-Doped Diamond Electrode for the Determination of Selected Biocides in Water Samples Katarzyna Mielech-Łukasiewicz * and Barbara Starczewska Institute of Chemistry, University of Białystok, Ciołkowskiego 1 K, 15-245 Białystok, Poland * Correspondence: [email protected]; Tel.: +48-85-738-80-65 Received: 24 June 2019; Accepted: 30 July 2019; Published: 31 July 2019 Abstract: In recent years, the remains of chemical substances in water environments, referred to as emerging organic contaminations, have been more and more often studied by analysts. This work shows the possibility of using a boron-doped diamond electrode to determine low concentration levels of remains of pharmaceuticals in environmental samples. The study focused on selected biocides from the group of azole fungicides (itraconazole and posaconazole) and was performed using quick and sensitive electrochemical methods. The cyclic voltammetry method was used in order to determine the properties of these compounds, whereas analytical characterization was performed using square wave voltammetry. The work involved the specification of the optimum electrooxidation conditions of the selected fungicides, their comparative characterization, and the development of a new, sensitive methods of itraconazole and posaconazole assay. The proposed procedures allowed us to determine itraconazole in the range from 7.9 10 8 to 1.2 10 6 moL L 1 and posaconazole in the range from × − × − · − 5.7 10 8 to 8.44 10 7 moL L 1. The relative standard deviation of the measurements did not × − × − · − exceed 5.85%. The developed procedures were successfully used to determine itraconazole and posaconazole concentration in water samples and the assay recovery was between 93.5% and 102.8%.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Electronic Claims Management Version 1.0 Engine User Manual
    Electronic Claims Management Engine (ECME) Version 1.0 User Manual May 2021 Department of Veterans Affairs Office of Information and Technology (OIT) Revision History Description (Patch # if Date Project Manager Technical Writer applicable) 05/2021 Updated for BPS*1*28 MCCF EDI TAS MCCF EDI TAS Updated Title Page date and ePharmacy ePharmacy footers Development Development Added Section 6.3.3 SC Team Team Prescriptions for Active Duty Prescriptions Added Section 8.1.11 Duplicate Claims Report 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx ePharmacy ePharmacy Claims Report Screen Display Development Development Updated Title Page date and Team Team footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option Electronic Claims Management Engine V. 1.0 User Manual ii May 2021 Description (Patch # if Date Project Manager Technical Writer applicable) 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Downloaded for Personal Non-Commercial Research Or Study, Without Prior Permission Or Charge
    https://theses.gla.ac.uk/ Theses Digitisation: https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ This is a digitised version of the original print thesis. Copyright and moral rights for this work are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Enlighten: Theses https://theses.gla.ac.uk/ [email protected] STUDIES OU THE MODE OF ACTION OF QUATERNARY AMMONIUM COMPOUNDS WITH MUSCLE RELAXANT AND OTHER PHARMACOLOGICAL ACTIVITIES A Thesis submitted to the University of Glasgow in candidature for the degree of Doctor of Philosophy in the Faculty of Medicine *y Thomas C. Muir, B.Sc., M.P.S. Division of Experimental Pharmacology, Institute of Physiology, The University, Glasgow. March 1962. ProQuest Number: 10656287 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10656287 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
    [Show full text]
  • B Ramamohima R
    I I CYTOPROTECTIVE ACTIONS PF NICOTINE: THE INCREASED EXPRESSION OF a.7 NICOTINIC RECEPTORS AND NGF/TrkA RECEPTORS ' . ' f !'b y' Ramamohima R. Jonnala ' ' ' I' Submitted to the Faculty o~the School of Graduate Studies of Medical College of Georgia in Partial Fulfillment of the Requirements of the Degree of Doctor of Philosophy Juiy, 2001 I' l Cytoprotective Actions of Nicotine: The Increased Expression of a.7 Nicotinic Receptors a-!ld NGF/TrkA Receptors This dissertation is submitted by Ramamohana R. Jonnala and has been examined and approved by an appointed committee of the faculty of the school of Graduate Studies of the Medical College of Georgia. The signatures which appear below verify the fact that all required changes have been incorporated and that the dissertation has received final approval with reference to content, form and accuracy of presentation. ' This dissertation is therefore in partial fulfillment of the requirements of the degree of Doctor of Philosophy. ACKNOWLEDGMENTS I would like to extend my appreciation to my major advisor, Dr. Jerry J. Buccafusco, for his guidance, encouragement and support. I would also like to thank my committee members, Dr. Alvin V. Terry Jr., Dr. William D. Hill, Dr. Nevin A. Lambert and Dr. Clare M. Bergson and also my thesis readers Dr. Debra Gearhart and Dr. Dale W. Sickles for their time and valuable suggestions. My sincere thanks to Dr. Deborah L. Lewis, Dr. Robert W. Caldwell and Dr. Gary C. Bond for encouraging me to enter the graduate program in the Department of Pharmacology & Toxicology, Medical College of Georgia. My sincere thanks to members of my laboratory Laura, Vanessa, Daniel, Cat, Mark, Nandu, Lu, and Shyamala for their assistance and suggestions.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]